PIM1 and leukemia: Chromatin immunoprecipitation assays have revealed that CDK6 is enriched at the FLT3 and PIM1 promoters and regulates the expression of FLT3 and PIM1 proteins.[28] Furthermore, the FLT3/HCK/CDK6 pathway led to the overexpression of CDK6 in FLT3-ITD AML cells, indicating a vicious cycle that enhances the survival and progression of leukemic cells.[25] Palbociclib targets not only the cell cycle but also FLT3 and PIM1 in FLT3-ITD, indicating its potential for use alone or in combination with FLT3 or PIM1 inhibitors in treating this subtype of leukemia.